1
|
Aleshina OA, Zakurdaeva K, Vasileva AN, Dubov SK, Dubov VS, Vorobyev VI, Butaev LS, Sukhareva AM, Gavrilova LV, Toropova IY, Popova MO, Siniaev AA, Kulagin AD, Kaplanov KD, Petrenko AA, Ochirova OI, Karpova A, Chelysheva EY, Turkina AG, Gurianova MA, Al-Radi LS, Gilyazitdinova EA, Egorova EK, Chabaeva YA, Kulikov SM, Sveshnikova YV, Kunst MA, Shuvaev V, Rakhmani AF, Panteleeva OL, Grishunina ME, Samoylova OS, Vorontsova E, Baryshnikova DV, Parovichnikova EN. Clinical Outcomes in Patients With COVID-19 and Hematologic Disease. Clin Lymphoma Myeloma Leuk 2023:S2152-2650(23)00128-3. [PMID: 37236904 PMCID: PMC10102503 DOI: 10.1016/j.clml.2023.04.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 03/30/2023] [Accepted: 04/07/2023] [Indexed: 05/28/2023]
Abstract
BACKGROUND Patients with hematologic diseases are at higher risk of the SARS-CoV-2 infection and more severe clinical outcomes of the coronavirus disease. CHRONOS19 is an observational prospective cohort study with the aim to determine the short and longer-term clinical outcomes, risk factors for disease severity and mortality, and rates of postinfectious immunity in patients with malignant and nonmalignant hematologic diseases and COVID-19. PATIENTS AND METHODS Overall, 666 patients were enrolled in the study, of which 626 were included in the final data analysis. The primary endpoint was 30-days all-cause mortality. Secondary endpoints included COVID-19 complications, rates of ICU admission and mechanical ventilation, outcomes of a hematologic disease in SARS-CoV-2 infected patients, overall survival, and risk factors for disease severity and mortality. Data from 15 centers were collected at 30, 90, and 180 days after COVID-19 was diagnosed and were managed using a web-based e-data capture platform. All evaluations were performed in the pre-omicron period of COVID-19 pandemic. RESULTS Thirty-days all-cause mortality was 18.9%. The predominant cause of death (in 80% of cases) were COVID-19 complications. At 180 days, the majority (70%) of additional deaths were due to hematologic disease progression. At a median follow-up of 5.7 [0.03-19.04] months, 6-months overall survival was 72% [95% CI: 0.69-0.76]. One-third of patients had severe SARS-CoV-2 disease. The rate of ICU admission was 22% with 77% of these patients requiring mechanical ventilation, with poor survival rate. A univariate analysis revealed that older age (≥ 60 years), male sex, malignant hematologic disease, myelotoxic agranulocytosis, transfusion dependence, refractory disease or relapse, diabetes among comorbidities, any complications, especially ARDS alone or in combination with CRS, admission to an ICU, and mechanical ventilation were associated with higher risks of mortality. Treatment of the hematologic disease was changed, postponed, or canceled in 63% of patients. At a longer follow-up (90 and 180 days), the status of the hematologic disease changed in 7.5% of patients. CONCLUSION Patients with hematologic disease and COVID-19 have high mortality rates, predominantly due to COVID-19 complications. At a longer-term follow-up, no significant impact of COVID-19 on the course of a hematologic disease was revealed.
Collapse
Affiliation(s)
- Olga A Aleshina
- National Medical Research Center for Hematology, Moscow, Russia.
| | | | | | | | | | | | - Lev S Butaev
- S.P. Botkin City Clinical Hospital, Moscow, Russia
| | | | | | | | - Marina O Popova
- R.M. Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia
| | - Aleksandr A Siniaev
- R.M. Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia
| | - Aleksandr D Kulagin
- R.M. Gorbacheva Research Institute, Pavlov University, Saint-Petersburg, Russia
| | | | | | | | - Alina Karpova
- N.A. Semashko Republican Clinical Hospital, Ulan-Ude, Russia
| | | | - Anna G Turkina
- National Medical Research Center for Hematology, Moscow, Russia
| | | | | | | | - Elena K Egorova
- National Medical Research Center for Hematology, Moscow, Russia
| | | | | | | | | | - Vasily Shuvaev
- Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia
| | | | | | | | - Olga S Samoylova
- N.A. Semashko Regional Clinical Hospital, Nizhniy Novgorod, Russia
| | | | | | | |
Collapse
|
2
|
Chelysheva EY, Petrova AN, Shukhov OA, Bykova AV, Nemchenko IS, Gurianova MA, Tsyba NN, Turkina AG. Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia. TERAPEVT ARKH 2022; 94:836-843. [DOI: 10.26442/00403660.2022.07.201747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 08/11/2022] [Indexed: 11/22/2022]
Abstract
Background. Withdrawal syndrome (WS) a musculoskeletal pain after discontinuation of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) has been described in the treatment-free remission (TFR) studies. The pathophysiological mechanisms and predisposing factors of WS have not been well established.
Aim. Our aim was to evaluate clinical features and factors associated with WS in the Russian cohort of CML patients who discontinued TKI therapy.
Materials and methods. WS was evaluated in total of 183 CML patients with chronic phase and sustained deep molecular response (DMR). WS was defined as a musculoskeletal pain newly observed after TKI cessation or as a worsening of previously observed symptoms.
Results. DMR loss free survival at 36 months was 49% and 43% in prospective and retrospective groups respectively (p=0.96) with mеdian (Me) time of observation 33 months (range 1136). WS was observed in 49 (27%) patients: grade 12 was in 45 (92%) patients, grade 3 in 4 (8%) patients. Me time to WS occurrence was 2 months (range 17), Ме duration of WS was 5 months (range 135). WS was resolved in 14 of 15 patients with molecular relapse after 13 months of TKI re-initiation and was decreased in 1 patient. WS was completely resolved in 31 of 34 patients who continued remained in TFR and decreased in 3 patients. WS was resolved spontaneously or with nonsteroidal anti-inflammatory drugs in 14 (45%) and 17 (55%) patients accordingly. Older age (p0.0001), longer duration of TKI therapy (p0.0001) and presence of locomotion system diseases (p=0.022) were observed in patients with WS. No WS was observed in pregnant patients (р0.001). Survival without DMR loss at 12 months after TKI stop was 66 and 42% in patients with and without WS accordingly (р=0.095).
Conclusion. The rate of WS was 27% that is in a good concordance with the data of the other TFR studies. A longer period of TKI exposure, older age and the history of locomotion system diseases were associated with the development of the WS. We found for the first time that WS was not observed in patients with pregnancy. There was no association of WS development and the rate of molecular relapses.
Collapse
|
3
|
Rea D, Mauro MJ, Hochhaus A, Boquimpani C, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley J, Cortes JE, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Minami Y. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.7004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7004 Background: Asciminib is the first BCR::ABL1 inhibitor to specifically target the ABL Myristoyl Pocket (STAMP). In the ASCEMBL primary analysis, asciminib had superior efficacy and better safety/tolerability than BOS in pts with CML-CP after ≥2 prior TKIs. After a median follow-up of 2.3 years (16.5 months’ additional follow-up since primary analysis), we report efficacy and safety results (cutoff: October 6, 2021). Methods: Eligible pts were adults with CML-CP after ≥2 prior TKIs, with intolerance or lack of efficacy per 2013 European LeukemiaNet. Pts were randomized 2:1 to asciminib 40 mg twice daily or BOS 500 mg once daily, stratified by major cytogenetic response (MCyR) status (Ph+ metaphases ≤35%) at baseline. The key secondary endpoint was major molecular response (MMR) rate at wk 96. Results: 233 pts were randomized to asciminib (n=157) or BOS (n=76). At cutoff, treatment was ongoing in 84 (53.5%) and 15 (19.7%) pts, respectively; the most common reason for discontinuation was lack of efficacy in 38 (24.2%) and 27 (35.5%) pts, respectively. MMR rate at wk 96 (per ITT) was higher on asciminib (37.6%) than BOS (15.8%). The difference, adjusting for baseline MCyR, was 21.7% (95% CI, 10.5%-33.0%; 2-sided P=.001). More pts on asciminib than BOS, respectively, had BCR::ABL1IS ≤1% (45.1% vs 19.4%) at wk 96. The probability of maintaining MMR and BCR::ABL1IS ≤1% for ≥72 wk was 96.7% (95% CI, 87.4%-99.2%) and 94.6% (95% CI, 86.2%-97.9%), respectively, on asciminib and 92.9% (95% CI, 59.1%-99.0%) and 95.0% (95% CI, 69.5%-99.3%), respectively, on BOS. Median duration of exposure was 103.1 (range, 0.1-201.1) wk on asciminib and 30.5 (range, 1.0-188.3) wk on BOS. Despite the longer duration of asciminib exposure, safety/tolerability of asciminib continued to be better than that of BOS (Table). No new on-treatment deaths were reported since the primary analysis. Most frequent (>10%) grade ≥3 adverse events (AEs) on asciminib vs BOS were thrombocytopenia (22.4%, 9.2%), neutropenia (18.6%, 14.5%), diarrhea (0%, 10.5%), and increased alanine aminotransferase (0.6%, 14.5%). Conclusions: After >2 years of follow-up, asciminib continued to show superior efficacy and better safety/tolerability vs BOS. Responses were durable, with more pts on asciminib in MMR. Additionally, more pts on asciminib had BCR::ABL1IS ≤1%, a milestone response in later lines associated with improved survival. These results continue to support the use of asciminib as a new CML therapy, with the potential to transform standard of care. Clinical trial information: NCT03106779. [Table: see text]
Collapse
Affiliation(s)
| | | | - Andreas Hochhaus
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany
| | - Carla Boquimpani
- HEMORIO, State Institute of Hematology Arthur de Siquiera Cavalcanti, Rio De Janeiro, Brazil
| | - Elza Lomaia
- Almazov National Medical Research Centre of Ministry of Health of Russian Federation, Saint Petersburg, Russian Federation
| | - Sergey Voloshin
- Russian Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation
| | - Anna G. Turkina
- National Research Center for Hematology, Moscow, Russian Federation
| | - Dong-Wook Kim
- Uijeongbu Eulji Medical Center, Uijeongbu-Si, South Korea
| | - Jane Apperley
- Centre for Haematology, Imperial College London, London, United Kingdom
| | - Jorge E. Cortes
- Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA
| | - Koji Sasaki
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | - Yosuke Minami
- Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan
| |
Collapse
|
4
|
Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Goh YT, Dyagil IS, Pagnano K, Batai A, Turkina AG, Leip E, Purcell S, Leone JM, Viqueira A, Cortes JE. Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.7009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7009 Background: BOS is approved for Philadelphia chromosome (Ph)+ CML resistant/intolerant to prior therapy and newly diagnosed Ph+ CP CML. In a phase 1/2 study, second-line BOS showed durable efficacy and manageable toxicity in pts with imatinib-resistant (IM-R) or -intolerant (IM-I) Ph+ CP CML. Methods: This final efficacy and safety analysis of the phase 1/2 study and extension study was based on ≥10 y of follow-up (FU). Ph+ CP CML pts who received BOS starting at 500 mg/d after prior treatment (Tx) with imatinib only were included. Results: 19% of pts were on BOS at y 10, and 13% were still on BOS at study completion after ≥10 y; 19% completed ≥10 y of FU. Median duration of Tx and FU were 26 and 54 mo, respectively. Median (range) dose intensity was 436 (87–599) mg/d. The most common primary reasons for permanent Tx discontinuation were lack of efficacy (unsatisfactory response or disease progression; 27%) and adverse events (AEs; 26%). In pts with a valid baseline assessment, cumulative complete cytogenetic response (CCyR), major molecular response (MMR) and MR4 rates (95% CI), respectively, were 50% (43–56), 42% (35–49) and 37% (30–44) (IM-R: 48% [41–56], 46% [37–55] and 39% [31–48]; IM-I: 53% [41–64], 36% [25–48] and 33% [22–45]). Responses were durable, with estimated probabilities of maintaining CCyR, MMR and MR4 > 50% after ≥10 y (Table). At 10 y, cumulative incidence of on-Tx progression/death was 24% and Kaplan-Meier (K-M) overall survival 72% (Table); 55 deaths (IM-R: n = 41; IM-I: n = 14) occurred on study, none BOS-related. Any grade Tx-emergent AEs (TEAEs) in ≥40% of pts were diarrhea (86%), nausea (46%) and thrombocytopenia (42%). Pleural effusion, cardiac and vascular TEAEs occurred in 13%, 12% and 11% of pts, respectively. 28% of pts had AEs leading to permanent Tx discontinuation; most common (≥2% of pts) were thrombocytopenia (6%), neutropenia (2%) and alanine aminotransferase increased (2%). Conclusions: These 10-y data are consistent with prior results of durable efficacy and manageable toxicity with second-line BOS and support long-term BOS use in CP CML pts after imatinib failure. Clinical trial information: NCT00261846 and NCT01903733. [Table: see text]
Collapse
Affiliation(s)
| | | | - Dong-Wook Kim
- Seoul St Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | - Yeow Tee Goh
- Singapore General Hospital, Singapore, Singapore
| | - Irina S Dyagil
- National Research Center for Radiation Medicine, Kiev, Ukraine
| | - Katia Pagnano
- Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil
| | - Arpad Batai
- Joint St. Stephen and St. László Hospital, Budapest, Hungary
| | - Anna G. Turkina
- National Research Center for Hematology, Moscow, Russian Federation
| | | | | | | | | | | |
Collapse
|
5
|
Gurianova MA, Chelysheva EY, Shukhov OA, Turkina AG. [Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review]. TERAPEVT ARKH 2020; 92:90-94. [PMID: 33346450 DOI: 10.26442/00403660.2020.07.000789] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Indexed: 11/22/2022]
Abstract
Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According to the current guidelines CML patients receive a long-term treatment with TKI in standard dose. The frequently observed adverse effects (AE) of TKI therapy are mostly dose-dependent. A new treatment approach with TKI use in reduced dose is desirable for the CML patients with existing AE or with a high risk of AE occurrence. We report the two cases of successful long-term treatment of CML patients with reduced doses of second generation TKIs. The aim of the TKI dose reduction was to reduce the clinical manifestations of drug toxicities and to prevent the AE.
Collapse
|
6
|
Lazareva OV, Turkina AG, Chelysheva EY, Kulikovsky AA, Galayko MV, Senderova OM, Pepeliaeva VM, Meresiy SV, Luchinin AS, Milutina GI, Gavrilova LV, Avdeeva LB, Dasheeva EB, Vinogradova OY, Julhakyan HL, Kulikov SM. Analysis of the Mortality of Russian Patients With Chronic Myeloid Leukemia in the Multicenter EUTOS ELN Population-based Study (EUTOS-PBS). Clin Lymphoma Myeloma Leuk 2020; 20:e328-e335. [PMID: 32192976 DOI: 10.1016/j.clml.2020.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 01/30/2020] [Accepted: 02/04/2020] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Russia took part in the multicenter population-based study (Europe) and included 6.8% adult patients with newly diagnosed chronic myeloid leukemia (CML). The objective of this study was to analyze the mortality in the Russian cohort of patients with newly diagnosed CML in the EUTOS PBS observational study. PATIENTS AND METHODS The analyzed cohort consisted of 197 patients (>18 years) with Ph+/BCR-ABL1+ CML diagnosed in the period from October 1, 2009 through December 31, 2012 from 6 regions of Russia. The distribution of the phases of CML were: chronic phase (CP), 93.4% and accelerated phase (AP) + blast crisis (BC), 6% + 0.6%. The median age was 50 years (range, 18-82 years); the male/female ratio was equal. RESULTS The overall survival (OS) at 5, 6, and 7 years was 80% (95% confidence interval [CI], 72%-86%), 78% (95% CI, 65%-80%), and 73% (95% CI, 65%-80%), respectively (P < .001). The 5-year OS in patients with AP and BC was 39%. In Russia, the study was prolonged, with a median follow-up of 77 months (range, 0.7-108 months): 141 (71.5%) patients were alive, 47 (24%) patients died, and the status of 9 (4.5%) patients is was unknown. Forty-seven (23.8%) patients died during the follow-up period. The largest number of deaths was observed in the first year after the CML diagnosis: 17 (36%) of 47 cases, 3 of 17 died refusing the CML treatment. At the seventh year of CML therapy, 1 patient died after allogenic hematopoietic stem cell transplantation. The causes of death were: (1) progression of CML to AP/BC in 20 (43%) patients; (2) death in remission in 5 (11%) patients with complete cytogenetic response (CCyR) and/or major molecular response; and (3) death without progression to AP/BC but with signs of leukemia in 22 (46%) patients. The 5-year cumulative incidence of death from all reasons was 20%; the cumulative incidence of CML-related and non-CML-related death at the fifth year was 18% and 11%, respectively. CONCLUSION In general, the results of treatment in the Russian population sample of non-selected patients with CML were comparable with the data of the total European cohort. The CML-related deaths prevailed in the first year of CML therapy. The appropriate monitoring and therapy interventions during the first year of CML treatment are apparently important for the long-term treatment results.
Collapse
Affiliation(s)
- Olga V Lazareva
- National Research Center for Hematology, Moscow, Russian Federation, Russia
| | - Anna G Turkina
- National Research Center for Hematology, Moscow, Russian Federation, Russia
| | | | - Anton A Kulikovsky
- National Research Center for Hematology, Moscow, Russian Federation, Russia
| | - Maria V Galayko
- Central Clinical Hospital No. 2 them. O.N. Semashko Russian Railways, Moscow, Russia
| | - Olga M Senderova
- Irkutsk Regional Clinical Hospital of the Order "Badge of Honor", Irkusk, Russia
| | | | - Sergey V Meresiy
- State Public Health Institution of Perm Region, "Clinical Medical Part No. 1", Perm, Russia
| | - Alexandr S Luchinin
- Federal State Budgetary Institution of Science "Kirov Research Institute of Hematology and Blood Transfusion of the Federal Medical and Biological Agency", Kirov, Russia
| | - Galina I Milutina
- State Autonomous Medical Institution - Bryansk Regional Hospital No. 1, Bryansk, Russia
| | - Lyubov V Gavrilova
- State Budgetary Healthcare Institution of the Republic of Mordovia, "Republican Clinical Hospital No. 4" of the Ministry of Health of the Russian Federation, Mordovia, Russia
| | - Lyudmila B Avdeeva
- State Healthcare Institution of the Trans-Baikal Territory, "Regional Clinical Hospital", Chita, Russia
| | - Elena B Dasheeva
- State Healthcare Institution, Zabaikalsky Regional Oncology Center, Chita, Russia
| | - Olga Yu Vinogradova
- Moscow City Hematology Center of the SP Botkin Memorial Hospital of the Moscow City Health Department, Moscow, Russia
| | - Hunan L Julhakyan
- National Research Center for Hematology, Moscow, Russian Federation, Russia.
| | - Sergey M Kulikov
- National Research Center for Hematology, Moscow, Russian Federation, Russia
| |
Collapse
|
7
|
Petinati NA, Petrova AN, Chelysheva EY, Shukhov OA, Bykova AV, Nemchenko IS, Sats NV, Turkina AG, Drize NI. Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid Leukemia before Discontinuation of Tyrosine Kinase Inhibitors. Bull Exp Biol Med 2019; 167:580-583. [PMID: 31502137 DOI: 10.1007/s10517-019-04575-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2019] [Indexed: 12/27/2022]
Abstract
We analyzed changes in multipotent mesenchymal stromal cells of patients with chronic myeloid leukemia before discontinuation of tyrosine kinase inhibitors. Withdrawal syndrome was significantly more common in patients who have been taking tyrosine kinase inhibitors for a longer time and in patients of older age and with lower body weight. In patients with withdrawal syndrome, the total production of mesenchymal stromal cells and expression of FGFR2 and MMP2 genes were significantly lower; loss of deep molecular response was also less frequent in this group of patients. At the same time, the expression of genes important for the maintenance of stem cells (SOX9, PDGFRa, and LIF) was significantly lower in the mesenchymal stromal cells of patients with withdrawal syndrome and loss of deep molecular response. We observed a clear-cut relationship between the development of withdrawal syndrome and the loss of deep molecular response. The decrease in the expression of FGFR2 and MMP2 genes in the mesenchymal stromal cells of patients with chronic myeloid leukemia before discontinuation of treatment can be a predictor of withdrawal syndrome, while simultaneous decrease in the expression of SOX9, PDGFRa, and LIF in these cells attests to undesirability of therapy discontinuation at the moment.
Collapse
Affiliation(s)
- N A Petinati
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - A N Petrova
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - E Yu Chelysheva
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - O A Shukhov
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - A V Bykova
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - I S Nemchenko
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | - N V Sats
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia
| | | | - N I Drize
- National Medical Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, Russia.
| |
Collapse
|
8
|
Hughes TP, Boquimpani C, Takahashi N, Benyamini N, Clementino NCD, Shuvaev V, Lipton JH, Turkina AG, De Paz Arias R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Kim DW, Fellague-Chebra R, Acharya S, Bouard C, Mahon FX. ENESTop 192-week results: Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib (NIL). J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.7005] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7005 Background: In the ENESTop study (NCT01698905) of TFR in pts with CML-CP who achieved a sustained deep molecular response (MR) with 2L NIL, 57.9% remained in TFR 48 wks after stopping NIL (primary endpoint). Analyses at 144 wks showed durability of TFR. Data from longer follow-up (192 wks) evaluating the maintenance of TFR are reported. Methods: Pts treated with ≥2 y NIL after > 4 wks imatinib (≥3 y total) and achieving MR4.5 ( BCR-ABL1IS ≤0.0032%) on NIL were eligible. After a 1 y consolidation, pts with no confirmed loss of MR4.5 could attempt TFR. NIL was resumed upon loss of major MR ( BCR-ABL1IS ≤0.1%) or confirmed loss of MR4 ( BCR-ABL1IS ≤0.01%). At the data cut-off (Sep 24 2018), all pts had completed ≥192 wks of TFR, resumed NIL, or discontinued the study. Results: By the data cut-off, of 126 pts entering TFR, 56 were ongoing, 59 had resumed NIL, and 11 had discontinued. TFR rate at 192 wks was 46.0% (58/126; 95% CI, 37.1–55.1%); all but 1 of the 58 pts were in MR4.5. Only 1/61 pts in TFR at 144 wks lost response by 192 wks (confirmed loss of MR4); another 2 pts discontinued due to serious AE (polycythemia vera) and pt/guardian decision, respectively. Of 59 pts who resumed NIL, 56 (94.9%) and 55 (93.2%) regained MR4 and MR4.5, respectively. 40/56 pts (71.4%) who regained MR4 had stable MR4 at 96 wks (12 discontinued < 96 wks, and 4 remained on study with < 96 wks, after regaining MR4); 37/55 pts (67.3%) who regained MR4.5 had stable MR4.5 at 96 wks (12 discontinued < 96 wks, and 6 remained on study with < 96 wks, after regaining MR4.5). There were no disease progressions, deaths due to CML, or new deaths since the 144-wk analysis. The 192 wk treatment-free survival rate was 50.3% (95% CI, 41.2–58.7%). Of 62 pts who remained in TFR for > 144 wks, 11.3%, 53.2%, 21.0%, 14.5% and 3.2% had musculoskeletal pain AEs during consolidation and each subsequent 48 wk period of TFR. Among 59 pts who resumed NIL, most common AEs were hypertension (20.3%) and arthralgia (13.6%); the majority of AEs were grade 1/2. Conclusions: Results demonstrate long-term durability and safety of TFR following 2L NIL, with no disease progressions or CML-related deaths, and musculoskeletal pain AEs were transient. Clinical trial information: NCT01698905.
Collapse
Affiliation(s)
- Timothy P. Hughes
- SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia
| | | | - Naoto Takahashi
- Department of Hematology, Akita University Hospital, Akita, Japan
| | | | | | - Vasily Shuvaev
- Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation
| | | | | | | | - Beatriz Moiraghi
- Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina
| | | | | | - Tomasz Sacha
- Department of Hematology, Jagiellonian University Hospital, Kraków, Poland
| | - Dong-Wook Kim
- Seoul St Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | | | | | | | - Francois-Xavier Mahon
- Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France
| |
Collapse
|
9
|
Lavrov AV, Chelysheva EY, Adilgereeva EP, Shukhov OA, Smirnikhina SA, Kochergin-Nikitsky KS, Yakushina VD, Tsaur GA, Mordanov SV, Turkina AG, Kutsev SI. Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients. BMC Med Genomics 2019; 12:37. [PMID: 30871622 PMCID: PMC6416830 DOI: 10.1186/s12920-019-0481-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Approximately 5-20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy. Gene polymorphisms, expression and microRNAs are known to be involved in the pathogenesis of TKI resistance in CML. The aim of our study is to find new molecular markers of TKI therapy efficacy in CML patients. METHODS Newly diagnosed patients with Ph+ CML in chronic phase were included in this study. Optimal and non-optimal responses to TKI were estimated according to ELN 2013 recommendation. We performed genotyping of selected polymorphisms in 62 blood samples of CML patients, expression profiling of 33 RNA samples extracted from blood and miRNA profiling of 800 miRNA in 12 blood samples of CML patients. RESULTS The frequencies of genotypes at the studied loci did not differ between groups of patients with an optimal and non-optimal response to TKI therapy. Analysis of the expression of 34,681 genes revealed 26 differently expressed genes (p < 0.05) in groups of patients with different TKI responses, but differences were very small and were not confirmed by qPCR. Finally, we did not find difference in miRNA expression between the groups. CONCLUSIONS Using modern high-throughput methods such as whole-exome sequencing, transcriptome and miRNA analysis, we could not find reliable molecular markers for early prediction of TKI efficiency in Ph+ CML patients.
Collapse
Affiliation(s)
- Alexander V Lavrov
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522. .,Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997.
| | - Ekaterina Yu Chelysheva
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167
| | - Elmira P Adilgereeva
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522
| | - Oleg A Shukhov
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167
| | - Svetlana A Smirnikhina
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522
| | - Konstantin S Kochergin-Nikitsky
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522
| | - Valentina D Yakushina
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522
| | - Grigory A Tsaur
- Regional Children Hospital 1, S. Deryabinoy str., 32, Ekaterinburg, Russian Federation, 620149.,Research Institute of Medical Cell Technologies, Soboleva str., 25, Ekaterinburg, Russian Federation, 620905.,Federal State Budgetary Educational Institution of Higher Education, Urals State Medical University of the Ministry of Healthcare of the Russian Federation, Repina str., 3, Ekaterinburg, Russian Federation, 620028
| | - Sergey V Mordanov
- Laboratory of Medical Genetics, The Rostov State Medical University, Nahichevansky av., 29, Rostov-on-Don, Russian Federation, 344022
| | - Anna G Turkina
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Novy Zykovki proezd, 4, Moscow, Russian Federation, 125167
| | - Sergey I Kutsev
- Laboratory of Mutagenesis, Federal State Budgetary Institution, Research Centre for Medical Genetics, Moskvorechie str., 1, Moscow, Russian Federation, 115522.,Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Ostrovityanova str., 1, Moscow, Russian Federation, 117997
| |
Collapse
|
10
|
Mahon FX, Boquimpani C, Takahashi N, Benyamini N, Clementino NCD, Shuvaev V, Merchant A, Lipton JH, Turkina AG, De Paz Arias R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Kim DW, Fellague-Chebra R, Acharya S, Chaturvedi S, Bouard C, Hughes TP. Long-term treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after stopping second-line (2L) nilotinib: ENESTop 144-wk results. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.7003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- François-Xavier Mahon
- Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France
| | | | - Naoto Takahashi
- Department of Hematology, Akita University Hospital, Akita, Japan
| | | | | | - Vasily Shuvaev
- Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation
| | - Akil Merchant
- Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Jeffrey H. Lipton
- Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
| | | | | | - Beatriz Moiraghi
- Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina
| | | | | | - Tomasz Sacha
- Department of Hematology, Jagiellonian University Hospital, Kraków, Poland
| | - Dong-Wook Kim
- Seoul St Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea, Republic of (South)
| | | | | | | | | | - Timothy P. Hughes
- SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia
| |
Collapse
|
11
|
Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med 2018; 168:461-470. [PMID: 29459949 DOI: 10.7326/m17-1094] [Citation(s) in RCA: 91] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND Treatment-free remission (TFR)-that is, stopping tyrosine kinase inhibitor (TKI) therapy without loss of response-is an emerging treatment goal in chronic myeloid leukemia (CML). OBJECTIVE To evaluate TFR after discontinuation of second-line nilotinib therapy. DESIGN Single-group, phase 2, open-label study. (ClinicalTrials.gov: NCT01698905). SETTING 63 centers in 18 countries. PATIENTS Adults with CML in chronic phase who received TKI therapy for at least 3 years (>4 weeks with imatinib, then ≥2 years with nilotinib) and achieved MR4.5 (BCR-ABL1 ≤0.0032% on the International Scale [BCR-ABL1IS]) while receiving nilotinib entered a 1-year consolidation phase. Those with sustained MR4.5 during consolidation were eligible to enter TFR. INTERVENTIONS Patients received nilotinib during consolidation; those who entered TFR stopped treatment. Patients with loss of major molecular response (MMR) (BCR-ABL1IS ≤0.1%) or confirmed loss of MR4 (BCR-ABL1IS ≤0.01%) during TFR reinitiated nilotinib treatment. MEASUREMENTS Proportion of patients without loss of MMR, confirmed loss of MR4, or treatment reinitiation within 48 weeks of stopping treatment (primary end point). RESULTS 163 patients who had switched from imatinib to nilotinib (for reasons including resistance, intolerance, and physician preference) enrolled in the study and entered the consolidation phase. Of these patients, 126 met the criteria for entering the TFR phase, and 73 (58% [95% CI, 49% to 67%]) and 67 (53% [CI, 44% to 62%]) maintained TFR at 48 weeks (primary end point) and 96 weeks, respectively. Of the 56 patients who reinitiated nilotinib therapy, 55 regained MMR or better and 52 regained MR4.5. None had CML progression to accelerated phase or blast crisis. Musculoskeletal pain was more frequent during the first 48 weeks after nilotinib discontinuation. LIMITATION The study included a heterogeneous patient population and was not designed to compare outcomes between patients continuing and those stopping treatment. CONCLUSION TFR seems achievable in patients with sustained MR4.5 after switching to nilotinib. PRIMARY FUNDING SOURCE Novartis Pharmaceuticals Corporation.
Collapse
Affiliation(s)
| | - Carla Boquimpani
- Hemocentro do Rio de Janeiro, HEMORIO, Rio de Janeiro, Brazil (C.B.)
| | - Dong-Wook Kim
- The Catholic University of Korea, Seoul, South Korea (D.K.)
| | | | | | - Vasily Shuvaev
- Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia (V.S.)
| | | | | | - Anna G Turkina
- National Research Center for Hematology, Moscow, Russia (A.G.T.)
| | | | - Beatriz Moiraghi
- Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina (B.M.)
| | | | | | - Tomasz Sacha
- Jagiellonian University Hospital, Kraków, Poland (T.S.)
| | | | | | | | - Stephane Wong
- Novartis Oncology Precision Medicine, Cambridge, Massachusetts (S.W.)
| | - Yu Jin
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Y.J.)
| | - Timothy P Hughes
- University of Adelaide, Adelaide, South Australia, Australia (T.P.H.)
| |
Collapse
|
12
|
Smirnikhina SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, Mozgovoy IV, Adilgereeva EP, Shukhov OA, Petrova AN, Bykova AV, Abdullaev AO, Turkina AG, Kutsev SI. Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation. Leuk Lymphoma 2018; 59:2512-2515. [PMID: 29424604 DOI: 10.1080/10428194.2018.1434880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Svetlana A Smirnikhina
- a Laboratory of Mutagenesis , FSBI "Research Centre for Medical Genetics" , Moscow , Russian Federation
| | - Ekaterina Yu Chelysheva
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Alexander V Lavrov
- a Laboratory of Mutagenesis , FSBI "Research Centre for Medical Genetics" , Moscow , Russian Federation.,c Department of Molecular and Cellular Genetics , The Russian National Research Medical University Named after N.I. Pirogov , Moscow , Russian Federation
| | | | - Ivan V Mozgovoy
- c Department of Molecular and Cellular Genetics , The Russian National Research Medical University Named after N.I. Pirogov , Moscow , Russian Federation
| | - Elmira P Adilgereeva
- a Laboratory of Mutagenesis , FSBI "Research Centre for Medical Genetics" , Moscow , Russian Federation
| | - Oleg A Shukhov
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Anna N Petrova
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Anastasia V Bykova
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Adhamjon O Abdullaev
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Anna G Turkina
- b Scientific and Advisory Department of Chemotherapy of Myeloproliferative disorders , FSFI "National Research Center for Hematology" of the Ministry of Healthcare of the Russian Federation , Moscow , Russian Federation
| | - Sergey I Kutsev
- a Laboratory of Mutagenesis , FSBI "Research Centre for Medical Genetics" , Moscow , Russian Federation.,c Department of Molecular and Cellular Genetics , The Russian National Research Medical University Named after N.I. Pirogov , Moscow , Russian Federation
| |
Collapse
|
13
|
Turkina AG, Chelysheva EY, Shuvaev VA, Gusarova GA, Bykova AV, Shukhov OA, Petrova AN, Vakhrusheva MV, Goryacheva SR, Kolosova LY, Krasikova PS, Fominykh MS, Martynkevich IS, Abdullaev AO, Sudarikov AB, Savchenko VG. [Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy]. TERAPEVT ARKH 2018; 89:86-96. [PMID: 29411766 DOI: 10.17116/terarkh2017891286-96] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
AIM To assess the results of following up patients with chronic myeloid leukemia (CML) and a deep molecular response (MR) without tyrosine kinase inhibitor (TKI) therapy. SUBJECTS AND METHODS The reasons for TKI discontinuation in 70 patients with CML and a deep MR of more than 1 year's duration were adverse events, pregnancy, and patients' decision. Information was collected retrospectively and prospectively in 2008-2016. RESULTS The median follow-up after TKI therapy discontinuation was 23 months (2 to 100 months). At 6, 12 and 24 months after TKI therapy discontinuation, the cumulative incidence of major MR (MMR) loss was 28, 41 and 48%, respectively; the survival rates without TKI therapy were 69, 50, and 39%, respectively. MMR loss was noted in 28 (88%) patients at 12 months; it was not seen without TKI therapy at 2-year follow-up. Deaths due to CML progression were absent. The Sokal risk group was a reliable factor influencing MMR loss (p ≤ 0.05). The cumulative recovery rate for deep MR after resumption of TKI use was 73 and 100% at 12 and 24 months, respectively, with a median follow-up of 24 months (1 to 116 months). Deep MR recovered at a later time when the therapy was resumed more than 30 days after MMR loss. CONCLUSION Safe follow-up is possible in about 50% of the patients with CML and stable deep MRs without TKI therapy. The introduction of this approach into clinical practice requires regular molecular genetic monitoring and organizational activities. Biological factors in maintaining remission after TKI discontinuation need to be separately studied.
Collapse
Affiliation(s)
- A G Turkina
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - E Yu Chelysheva
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - V A Shuvaev
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint Petersburg, Russia
| | - G A Gusarova
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A V Bykova
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - O A Shukhov
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A N Petrova
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - M V Vakhrusheva
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - S R Goryacheva
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - L Yu Kolosova
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - P S Krasikova
- Orenburg Regional Clinical Hospital, Orenburg, Russia
| | - M S Fominykh
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint Petersburg, Russia
| | - I S Martynkevich
- Russian Research Institute of Hematology and Transfusiology, Federal Biomedical Agency of Russia, Saint Petersburg, Russia
| | - A O Abdullaev
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A B Sudarikov
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - V G Savchenko
- National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|
14
|
Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih L, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, Lipton JH. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol 2017; 179:219-228. [PMID: 28699641 PMCID: PMC5655928 DOI: 10.1111/bjh.14829] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 05/29/2017] [Indexed: 01/20/2023]
Abstract
The Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Extending Molecular Responses (ENESTxtnd) study was conducted to evaluate the kinetics of molecular response to nilotinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase and the impact of novel dose-optimization strategies on patient outcomes. The ENESTxtnd protocol allowed nilotinib dose escalation (from 300 to 400 mg twice daily) in the case of suboptimal response or treatment failure as well as dose re-escalation for patients with nilotinib dose reductions due to adverse events. Among 421 patients enrolled in ENESTxtnd, 70·8% (95% confidence interval, 66·2-75·1%) achieved major molecular response (BCR-ABL1 ≤ 0·1% on the International Scale) by 12 months (primary endpoint). By 24 months, 81·0% of patients achieved major molecular response, including 63·6% (56 of 88) of those with dose escalations for lack of efficacy and 74·3% (55 of 74) of those with dose reductions due to adverse events (including 43 of 54 patients with successful re-escalation). The safety profile of nilotinib was consistent with prior studies. The most common non-haematological adverse events were headache, rash, and nausea; cardiovascular events were reported in 4·5% of patients (grade 3/4, 3·1%). The study was registered at clinicaltrials.gov (NCT01254188).
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Cardiovascular Diseases/chemically induced
- Cardiovascular Diseases/epidemiology
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/epidemiology
- Male
- Middle Aged
- Prospective Studies
- Pyrimidines/administration & dosage
- Pyrimidines/adverse effects
Collapse
Affiliation(s)
- Timothy P. Hughes
- South Australian Health and Medical Research Institute (SAHMRI)University of AdelaideSA PathologyAdelaideSAAustralia
| | - Eduardo Munhoz
- Hospital Erasto Gaertner – Liga Paranaense Combate ao CâncerCuritibaBrazil
| | - Marco Aurelio Salvino
- Hospital São Rafael‐Monte Tabor & Hospital Universitario Professor Edgard Santos‐Universidade Federal da BahiaSalvadorBrazil
| | | | | | - Jake Shortt
- School of Clinical Sciences at Monash HealthMonash UniversityClaytonVic.Australia
| | - Hang Quach
- St Vincent's HospitalUniversity of MelbourneMelbourneVic.Australia
| | - Carolina Pavlovsky
- FUNDALEUHospitalization and Clinical Research CentreBuenos AiresArgentina
| | | | - Lee‐Yung Shih
- Chang Gung Memorial Hospital‐LinkouChang Gung UniversityTaoyuan CityTaiwan
| | - Anna G. Turkina
- FGB Haematology Research Centre Health Ministry Research FacilityMoscowRussia
| | - Luis Meillon
- Hospital de EspecialidadesCMN Siglo XXIMexico CityMexico
| | - Yu Jin
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | | | - Darshan Dalal
- Novartis Pharmaceuticals CorporationEast HanoverNJUSA
| | | |
Collapse
|
15
|
Sokolova MA, Turkina AG, Melikian AL, Sudarikov AB, Treglazova SA, Shukhov OA, Gemdzhian EG, Abdullaev AО, Kovrigina AM, Misyurin AV, Pliskunova YV, Ivanova VL, Moiseeva TN. [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera]. TERAPEVT ARKH 2017; 88:69-77. [PMID: 28139563 DOI: 10.17116/terarkh2016881269-77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
AIM To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). SUBJECTS AND METHODS A total of 61 patients (41 with ET and 20 with PV) were examined. Prior to study enrolment, 44 (72%) patients with ET or PV received one or other therapy (aspirin was not taken into account). The mean Jak2V617F mutant allele at baseline was 23% (6-54%) in the patients with ET and 40% (11-88%) in those with PV. The median time from diagnosis to enrollment was 49 months. RESULTS The paper presents the clinical and molecular findings of long-term INF-α therapy in patients with ET or PV. The median follow-up was 52 months. Recombinant IFN-α2 showed its ability to induce complete hematologic remission (ET (76%), PV (70%)) and a complete molecular response. 22 (69%) out of 32 patients were noted to have a smaller number of cells with the Jak2V617F mutation. In the patients with PV and in those with ET, the relative reduction in the proportion of cells with the Jak2V617F mutant gene averaged 85% and 56% of the baseline values, respectively. There was a reduction in the proportion of cells expressing the Jak2V617F mutation in both the ET (from 12 to 2.2%; p=0.001) and PV (from 32.7% to 3.2%) groups (р=0.001). Ten (31%) patients achieved a deep molecular remission (≤2% Jak2V617F allele); among them, 5 patients were not found to have Jak2V617F mutation. The obtained molecular response remained in 7 of the 10 patients untreated for 11 to 86 months. The long-term treatment with IFN-α led to normalization of the morphological pattern of bone marrow in 5 of the 7 PV or ET patients. CONCLUSION Significant molecular remissions achieved by therapy with recombinant interferon-α2 confirm the appropriateness of this treatment option in in the majority of patients with ET or PV.
Collapse
Affiliation(s)
- M A Sokolova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A G Turkina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A L Melikian
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A B Sudarikov
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - S A Treglazova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - O A Shukhov
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - E G Gemdzhian
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A О Abdullaev
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A M Kovrigina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A V Misyurin
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - Yu V Pliskunova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - V L Ivanova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - T N Moiseeva
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|
16
|
Tsyba NN, Turkina AG, Chelysheva EY, Nemchenko IS, Kovrigina AM, Obukhova TN, Urnova ES, Kuzmina LA, Savchenko VG. [A rare case of myeloproliferative disease with t(8;13)(p11;q12) associated with eosinophilia and lymphadenopathy]. TERAPEVT ARKH 2016; 88:98-103. [PMID: 27459622 DOI: 10.17116/terarkh201688798-103] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Myeloproliferative disease associated with FGFR1 rearrangement (8p11), which is included in the 2008 WHO Classification of Myeloid Neoplasms, is a rare and extremely aggressive abnormality. The paper describes a clinical case of a 39-year-old female patient who was detected to have leukocytosis (as high as 47.2·109/l), absolute eosinophilia (as high as 3.1·109/l), and enlarged peripheral lymph nodes during her visit to a doctor. The bone marrow (BM) showed the changes typically encountered in myeloproliferative disease with eosinophilia. The patient was found to have t(8;13)(p11;q12) translocation associated with the rearrangement of the FGFR1 gene located at the 8p11 locus. Molecular and cytogenetic examinations failed to reveal BCR-ABL chimeric transcript, Jak2 V617F mutation, and deletions and translocations involving PDGFRA (4q12) and PDGFRB (5q32-33). The similar changes in the karyotype were also found in the lymph node cells. The undertaken treatment with hydroxyurea and the tyrosine kinase inhibitor dasatinib turned out to be ineffective. The patient underwent allogeneic BM transplantation from a HLA-identical sibling. Graft rejection occurred 6 months later. Allogeneic BM transplantation from the same donor (100% donor chimerism; FGFR1/8р11 translocation was not detected), which was complicated by the development of chronic graft-versus-host reaction, was performed again in March 2015. The patient is being followed up and continues to receive immunosuppressive therapy.
Collapse
Affiliation(s)
- N N Tsyba
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A G Turkina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - E Yu Chelysheva
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - I S Nemchenko
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - A M Kovrigina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - T N Obukhova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - E S Urnova
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - L A Kuzmina
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| | - V G Savchenko
- National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|
17
|
Hughes TP, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz Arias R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Mahon FX. Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.7054] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Timothy P Hughes
- South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, Australia
| | | | - Dong-Wook Kim
- Catholic Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea
| | - Noam Benyamini
- Hematology Institute of Rambam Health Care Campus, Haifa, Israel
| | | | - Vasily Shuvaev
- Russian Research Institute of Hematology and Transfusiology,, Saint-Petersburg, Russian Federation
| | | | | | | | | | - Beatriz Moiraghi
- Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina
| | | | | | - Tomasz Sacha
- Hematology Department, Jagiellonian University, Krakow, Poland
| | - Naoto Takahashi
- Department of Hematology, Akita University Hospital, Akita, Japan
| | | | | | | | - Yu Jin
- Novartis Pharmaceuticals Corp, East Hanover, NJ
| | | |
Collapse
|
18
|
Lavrov AV, Chelysheva EY, Smirnikhina SA, Shukhov OA, Turkina AG, Adilgereeva EP, Kutsev SI. Frequent variations in cancer-related genes may play prognostic role in treatment of patients with chronic myeloid leukemia. BMC Genet 2016; 17 Suppl 1:14. [PMID: 26822197 PMCID: PMC4895599 DOI: 10.1186/s12863-015-0308-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Genome variability of host genome and cancer cells play critical role in diversity of response to existing therapies and overall success in treating oncological diseases. In chronic myeloid leukemia targeted therapy with tyrosine kinase inhibitors demonstrates high efficacy in most of the patients. However about 15 % of patients demonstrate primary resistance to standard therapy. Whole exome sequencing is a good tool for unbiased search of genetic variations important for prognosis of survival and therapy efficacy in many cancers. We apply this approach to CML patients with optimal response and failure of tyrosine kinase therapy. RESULTS We analyzed exome variations between optimal responders and failures and found 7 variants in cancer-related genes with different genotypes in two groups of patients. Five of them were found in optimal responders: rs11579366, rs1990236, rs176037, rs10653661, rs3803264 and two in failures: rs3099950, rs9471966. These variants were found in genes associated with cancers (ANKRD35, DNAH9, MAGEC1, TOX3) or participating in cancer-related signaling pathways (THSD1, MORN2, PTCRA). CONCLUSION We found gene variants which may become early predictors of the therapy outcome and allow development of new early prognostic tests for estimation of therapy efficacy in CML patients. Normal genetic variation may influence therapy efficacy during targeted treatment of cancers.
Collapse
Affiliation(s)
- Alexander V Lavrov
- Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia. .,Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Moscow, Russia.
| | - Ekaterina Y Chelysheva
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Svetlana A Smirnikhina
- Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia
| | - Oleg A Shukhov
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Anna G Turkina
- Scientific and Advisory Department of Chemotherapy of Myeloproliferative Disorders, Federal State-Funded Institution National Research Center for Hematology of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
| | - Elmira P Adilgereeva
- Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia
| | - Sergey I Kutsev
- Laboratory of Mutagenesis, Federal State Budgetary Institution "Research Centre for Medical Genetics", Moskvorechie, 1, Moscow, 115478, Russia.,Department of Molecular and Cellular Genetics, State Budgetary Educational Institution of Higher Professional Education "Russian National Research Medical University named after N.I. Pirogov" of Ministry of Health of the Russian Federation, Moscow, Russia
| |
Collapse
|
19
|
Gambacorti‐Passerini C, Kantarjian HM, Kim D, Khoury HJ, Turkina AG, Brümmendorf TH, Matczak E, Bardy‐Bouxin N, Shapiro M, Turnbull K, Leip E, Cortes JE. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol 2015; 90:755-68. [PMID: 26040495 PMCID: PMC5132035 DOI: 10.1002/ajh.24034] [Citation(s) in RCA: 56] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2015] [Accepted: 04/04/2015] [Indexed: 01/24/2023]
Abstract
Long-term efficacy and safety of bosutinib (≥4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in ∼50% AP responders at 4 years (∼25% BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.
Collapse
Affiliation(s)
| | - Hagop M. Kantarjian
- Department of LeukemiaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHoustonTexas
| | - Dong‐Wook Kim
- Department of HematologySeoul St. Mary's HospitalSeoulSouth Korea
| | - Hanna J. Khoury
- Division of HematologyWinship Cancer Institute of Emory UniversityAtlantaGeorgia
| | | | - Tim H. Brümmendorf
- Clinic for OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum Aachen, RWTH AachenGermany
- OncologyHematologyand Stem Cell TransplantationUniversitätsklinikum Hamburg‐EppendorfHamburgGermany
| | | | | | | | | | | | - Jorge E. Cortes
- Department of LeukemiaDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHoustonTexas
| |
Collapse
|
20
|
Nemchenko IS, Turkina AG, Chelysheva EY, Galstyan GM, Kovrigina AM, Khuazheva NK, Savchenko VG. [FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy]. TERAPEVT ARKH 2015; 87:89-95. [PMID: 26978425 DOI: 10.17116/terarkh2015871289-95] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The described case of FIP1L1-PDGFRА-positive myeloproliferative disease is characterized by an atypical aggressive course to develop severe specific complications as injuries to the brain, heart, lung, and intestine. Pathogenetic therapy with imatinib could stabilize a patient's state, but failed to produce a complete hematological response. Switching from imatinib to dasatinib could produce sustained clinical, hematological, and molecular remissions.
Collapse
Affiliation(s)
- I S Nemchenko
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| | - A G Turkina
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| | - E Yu Chelysheva
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| | - G M Galstyan
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| | - A M Kovrigina
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| | - N K Khuazheva
- S.P. Botkin City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia
| | - V G Savchenko
- Hematology Research Center, Ministry of Health of Russia, Moscow, Russia
| |
Collapse
|
21
|
Gambacorti‐Passerini C, Brümmendorf TH, Kim D, Turkina AG, Masszi T, Assouline S, Durrant S, Kantarjian HM, Khoury HJ, Zaritskey A, Shen Z, Jin J, Vellenga E, Pasquini R, Mathews V, Cervantes F, Besson N, Turnbull K, Leip E, Kelly V, Cortes JE. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol 2014; 89:732-42. [PMID: 24711212 PMCID: PMC4173127 DOI: 10.1002/ajh.23728] [Citation(s) in RCA: 80] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 04/02/2014] [Indexed: 11/24/2022]
Abstract
Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n = 200) or intolerant (n = 88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. http://ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732–742, 2014. © 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | - Tim H. Brümmendorf
- Universitätsklinikum AachenRWTH Aachen Germany
- Universitätsklinikum Hamburg‐EppendorfHamburg Germany
| | | | | | - Tamas Masszi
- St. István and St. László HospitalBudapest Hungary
| | - Sarit Assouline
- Jewish General Hospital, McGill UniversityMontreal QC Canada
| | | | | | - H. Jean Khoury
- Winship Cancer Institute of Emory UniversityAtlanta Georgia
| | - Andrey Zaritskey
- University of Pavlov and Almazov Federal Heart, Blood, and Endocrinology Centre, StPetersburg Russia
| | | | - Jie Jin
- First Affiliated Hospital, Zhejiang University School of MedicineHangzhou Zhejiang China
| | - Edo Vellenga
- University of Groningen and University Medical Center GroningenGroningen Netherlands
| | - Ricardo Pasquini
- Hospital das Clínicas da Universidade Federal do ParanáParaná Brazil
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Kulikov SM, Vinogradova OI, Chelysheva EI, Tishchenko IA, Galaĭko MA, Lazareva OV, Senderova OM, Pepeliaeva VM, Meresiĭ SV, Luchinin AS, Ovsepian VA, Miliutina GI, Gavrilova LV, Avdeeva LB, Neverova AL, Turkina AG. [Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study]. TERAPEVT ARKH 2014; 86:24-30. [PMID: 25314774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM To assess the main epidemiological characteristics of chronic myeloid leukemia (CML) in the Russian Federation. SUBJECTS AND METHODS A planned epidemiological prospective study was conducted in 2009-2012 in 6 Russian regions with the total number of 10.1 million inhabitants, which notified all new CML cases. RESULTS The unstandardized (unnormalized, baseline) recorded incidence of CML in the examined regions was 0.58 per 100,000 annually. Its standardized (normalized) incidence was 0.70 for the WHO standard population and 0.72 for the European standard population. The regional variations in the incidence were 0.44 to 0.69. The structural analysis of the incidence in the age strata indicated that the overall morbidity was less due to the decreased rate of registration in old age groups. The morbidity rates in patients aged less than 60 years were nearly similar to the European rates; those in patients aged over 70 years were almost 10 times lower. The lower rate of detection and screening diagnosis of CML in pensioners in primary health care is discussed. CONCLUSION The data obtained in this study may serve as the starting point for monitoring the CML epidemiological situation.
Collapse
|
23
|
Melikian AL, Kolosheĭnova TI, Goriacheva SR, Subortseva IN, Vakhrusheva MV, Kolosova EN, Sudarikov AB, Abdullaev AO, Dvirnyk VN, Varlamova EI, Kovrigina AM, Turkina AG. [Synchronous and metachronous myeloid and lymphoid tumors]. TERAPEVT ARKH 2014; 86:37-44. [PMID: 25314776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
AIM To determine the clinical features of multiple primary tumors (MPT) in patients with hemoblastoses, to develop treatment policy for synchronous and metachronous tumors, and to determine the impact of chemotherapy for one disease on the course and prognosis of another one. SUBJECTS AND METHODS The investigation included 20 patients with multiple primary synchronous and metachronous myeloid and lymphoid tumors, who had been followed up at the Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation. The distribution of patients by nosological entities was as follows: 17 (85%) patients with myeloproliferative diseases (MPDs) concurrent with lymphoproliferative diseases (LPDs) and 3 (15%) with two types of MPD. A special group comprised 3 patients who successively developed 3 malignant diseases: cancer/B-cell chronic lymphocytic leukemia (B-CLL)/Ph-positive chronic myeloid leukemia (Ph+CML); cancer/polycythemia vera (PCV)/B-CLL; cancer/essential thrombocythemia (ETC)/multiple myeloma (MM). RESULTS The Outpatient Department of the Hematology Research Center, Ministry of Health of the Russian Federation, followed up 20 patients with synchronous and metachronous tumors in 1996 to 2013. The patients' age was 42 to 82 years (64 years). The female/male ratio was 1:1.2. Metachronous tumors were 1.5-fold higher than synchronous ones. The time to detection of secondary hemoblastosis averaged 3.3 years; the longest interval was 14 years; the mean coexistence of 2 tumors was 4.8 years (1-11 years). The total length of the follow-up was 8 years (1-19 years). Among them, there were 17 (85%) patients with 2 chronic hematologic tumors with a myeloid or lymphoid phenotype; 3 (15%) of the 20 patients had 3 malignant diseases (cancer/ B-CLL)/Ph+CML, cancer/PCV/B-CLL, cancer/ETC/MM. In the group of 17 patients, 13 (76%) were diagnosed as having Ph-negative MPDs (PCV in 4 patients, primary myelofibrosis in 4, ETC in 4, undifferentiated MPD in1) and 4 (24%) patients had Ph+CML. This patient group was found to have the following LPDs: CLL in 5 (30%), hairy cell leukemia in 1 (5%), paraproteinemic hemoblastoses in 11 (65%). MPD preceded LPD in 8 (47%) patients; the development interval between two tumors averaged 6 years (1 to 14 years). LPD preceded MPD in 3 (18%) patients; the interval averaged 5 years (2 to 17 years). MPD and LPD appeared synchronously in 6 (35%) patients. CONCLUSION The fact that 2 malignancies or more may occur in one patient determines the need for a careful follow-up of patients with blood system diseases. The activity of one hematologic disease or another is a leading criterion for choosing a therapeutic tactic.
Collapse
|
24
|
Saglio G, Hughes TP, Larson RA, Issaragrilsil S, Turkina AG, Steegmann JL, Lopez JL, Nakaseko C, Kalaycio ME, Huguet F, Kemp CN, Fan X, Menssen HD, Kantarjian HM, Hochhaus A. Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.7054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7054^ Background: ENESTnd demonstrated the superiority of NIL to IM in pts with newly diagnosed CML-CP, such as higher rates of molecular response (MR) and reduced risk of progression to accelerated phase (AP)/blast crisis (BC). This landmark analysis of ENESTnd is based on BCR-ABL transcript levels at 3 mo, with 4 y of follow-up. Methods: Rates of major MR (MMR; BCR-ABLIS ≤ 0.1%), MR4.5 (BCR-ABLIS≤ 0.0032%), progression to AP/BC, overall survival (OS), and progression-free survival (PFS) in pts in the NIL 300 mg twice daily (BID; n = 282) and IM 400 mg once daily (QD; n = 283) arms of ENESTnd were evaluated based on 3-mo BCR-ABL levels (≤ 10% vs > 10%). Results: More pts treated with NIL than IM achieved BCR-ABL ≤ 10% at 3 mo (91% vs 67%; Table). Other factors associated with MR at 3 mo included Sokal risk, spleen size, chromosomal abnormalities, white blood cell count, and median dose intensity (for NIL). On both arms, pts with BCR-ABL ≤ 10% at 3 mo had significantly higher rates of MMR and MR4.5and significantly improved PFS and OS than pts with BCR-ABL > 10% at 3 mo. Of the pts with BCR-ABL > 10% at 3 mo, 2 on NIL (8%) and 14 on IM (16%) progressed to AP/BC on study. Half of these progressions occurred between 3 and 6 mo. Analyses of outcomes based on BCR-ABL levels at 6 mo were similar to findings based on 3-mo data. Conclusions: BCR-ABL levels ≤ 10% at 3 mo were associated with superior outcomes, including higher rates of MR4.5 by 4 y and lower risk of disease progression. More pts treated with NIL than IM achieved this early level of MR. Clinical trial information: NCT00471497. [Table: see text]
Collapse
Affiliation(s)
- Giuseppe Saglio
- University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy
| | - Timothy P. Hughes
- Centre for Cancer Biology, SA Pathology, University of Adelaide, Adelaide, Australia
| | | | | | | | | | - Jose L. Lopez
- Banco Municipal de Sangre, Dpt. Clinicas Hematologicas, Esq. Pirineos, Caracas, DC, Venezuela
| | - Chiaki Nakaseko
- Chiba University Hospital, Department of Hematology, Chiba, Japan
| | | | | | | | - Xiaolin Fan
- Novartis Pharmaceuticals Corp, East Hanover, NJ
| | | | | | - Andreas Hochhaus
- Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany
| |
Collapse
|
25
|
Turkina AG, Chelysheva EI. [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects]. TERAPEVT ARKH 2013; 85:4-9. [PMID: 24137941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Over the past decade the clinical introduction of agents that directionally blocks the activity of BCR-ABL tumor tyrosine kinase (TK) has changed the prognosis of chronic myeloid leukemia. A significant malignant Ph'-positive clone inhibition and durable remissions have made it possible to increase overall and relapse-free survival. Due to their higher life expectancy, the number of patients is on the increase and their quality of life and working capacity remain good. According to the All-Russian Register of Chronic Myeloid Leukemia, there were more than 6500 cases in the Russian Federation in 2012. Of them, 93.1% were diagnosed with the chronic phase of the disease, 6.4 and 0.4% with its accelerated phase and blast crisis, respectively. Among the BCR-ABL TK inhibitors (TKI) registered in the Russian Federation and recommended for the treatment of chronic myeloid leukemia, there are 3 medications: imatinib, nilotinib, and dasatinib. The efficiency and safety of TKI therapy have been well studied. The most important principle of treatment is to permanently affect the Ph'-positive tumor cell clone by the long-term daily use of TKls. Regular cytogenetic and molecular genetic monitoring allows adequate estimation of the leukemic clone volume and it is essential in evaluating the therapeutic effectiveness. To choose a TKI for each specific patient with regard for its best tolerability and maximum efficiency permits individualized treatment. The prospect of therapy discontinuation can be discussed only in individual patients with a durable and stable complete molecular response and only within clinical trials.
Collapse
|
26
|
Stakhina OV, Turkina AG, Kostina IE, Kochkareva IB. [A rare complication of imatinib mesylate therapy: drug-induced pneumonitis]. TERAPEVT ARKH 2010; 82:59-61. [PMID: 20387680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The use of imatinib mesylate (Glivec) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has increased 7-year survival and improved the prognosis of the disease. The drug is generally tolerated well; the proportion of patients in whom imatinib treatment results in the development of toxic complications is small. Drug-induced interstitial pneumonitis associated with imatinib therapy is a rare complication that requires timely differential diagnosis, discontinuation of an inductor (imatinib), and altered further treatment policy.
Collapse
|
27
|
Grineva NI, Akhlynina TV, Gerasimova LP, Manakova TE, Sarycheva NG, Schmarov DA, Tumofeev AM, Nydenova NM, Kolosova LY, Kolosheynova TI, Kovaleva LG, Kuznetsov SV, Vorontsova AV, Turkina AG. Cell Regulation of Proliferation and Differentiation ex vivo for Cells Containing Ph Chromosome in Chronic Myeloid Leukemia. Acta Naturae 2009. [DOI: 10.32607/20758251-2009-1-3-108-120] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Grineva NI, Akhlynina TV, Gerasimova LP, Manakova TE, Sarycheva NG, Schmarov DA, Tumofeev AM, Nydenova NM, Kolosova LY, Kolosheynova TI, Kovaleva LG, Kuznetsov SV, Vorontsova AV, Turkina AG. Cell Regulation of Proliferation and Differentiation ex vivo for Cells Containing Ph Chromosome in Chronic Myeloid Leukemia. Acta Naturae 2009. [DOI: 10.32607/actanaturae.10791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Grineva NI, Akhlynina TV, Gerasimova LP, Manakova TE, Sarycheva NG, Schmarov DA, Tumofeev AM, Nydenova NM, Kolosova LY, Kolosheynova TI, Kovaleva LG, Kuznetsov SV, Vorontsova AV, Turkina AG. Cell Regulation of Proliferation and Differentiation ex vivo for Cells Containing Ph Chromosome in Chronic Myeloid Leukemia. Acta Naturae 2009; 1:108-20. [PMID: 22649623 PMCID: PMC3347536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Cell regulation of Ph(+)cell proliferation and differentiation has been studied ex vivo in various chronic myeloid leukemia (CML) patients. The regulation is provided by alternation of effective stages of proliferation and maturation with inhibition of Ph(+) cell proliferation by accumulating neutrophils under apoptosis blockage. The alternation of stages consists of switching stage 1 (effective proliferation) to stage 2 (effective maturation) and proceeds according to the 1/2 -1/2/1 or 2/1-2/1/2/1 schemes. The kinetic plots of alternations pass through control points of crossing plots, where the parameters of proliferation and maturation are equal. The indices of P/D efficiency (ratio of proliferation and maturation rates) are 1.06±0.23 and don't depend on time, alternation order, or sources of Ph(+) cells - CML patients. During stages alternation, conversely, the parameters of Ph+ cell proliferation and maturation vary. The proliferation stages are characterized by increased proliferating cells content, a decreased number of neutrophils, and apoptosis induction. At the maturation stages, conversely, apoptosis is inhibited, the number of mature neutrophils increases, while immature Ph(+) cells decrease. High content neutrophils inhibit the proliferation of Ph(+) cells and impair their own maturation by inversion of maturation order, probably through a feedback mechanism. The regulation differences ex vivo reveal three types of Ph(+) cells from various individual CML patients, distinguished by the number and duration of alternating stages of proliferation and maturation. Ph(+) cells types 1 and 2 have one prolonged stage of effective proliferation or effective maturation with efficiency indices P/D(1) = 1-20 or P/D(2) ⇐ 1. At the same time period, the proliferation and differentiation of the Ph(+) cells type 3 proceeds with repeated alternations of stages with P/D(1) = 1-4 or P/D(2) ⇐ 1. Type 1 Ph(+) cells (~20%) were isolated from patients in advanced stages of CML, while Ph(+) cells types 2 and 3 (30 and 50% correspondingly) were isolated from CML chronic phase patients sensitive to chemotherapy.
Collapse
Affiliation(s)
- N I Grineva
- GU National Research Center for Hematology, Russian Academy of Medical Sciences
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Turkina AG, Domracheva EV, Vorontsova AV, Aseeva EA, Vinogradova OI, Stakhina OV, Gusarova GA, Diagileva OA, Semenova EA, Vakhrusheva MV, Kolosheĭnova TI, Abakumov EM, Chelysheva EI, Goriacheva SR, Ivanova TV, Zakharova ES, Kolosova LI, Zakharova AV, Naumova IN, Diachenko LV, Kulikov SM, Kovaleva LG, Khoroshko ND. [Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases]. TERAPEVT ARKH 2009; 81:29-36. [PMID: 19708570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
AIM To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK). MATERIAL AND METHODS A total of 386 patients with CML (chronic phase--288, acceleration phase--77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand--investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made. RESULTS The existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients. CONCLUSION Detection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.
Collapse
MESH Headings
- Adult
- Benzamides
- Bone Marrow Cells/drug effects
- Bone Marrow Cells/enzymology
- Bone Marrow Cells/pathology
- Chromosomes, Human, Pair 8/genetics
- Drug Administration Schedule
- Female
- Fusion Proteins, bcr-abl/antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Karyotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Male
- Middle Aged
- Philadelphia Chromosome/drug effects
- Piperazines/administration & dosage
- Piperazines/therapeutic use
- Protein Kinase Inhibitors/administration & dosage
- Protein Kinase Inhibitors/therapeutic use
- Pyrimidines/administration & dosage
- Pyrimidines/therapeutic use
- Time Factors
- Trisomy
Collapse
|
31
|
Vinogradova OI, Turkina AG, Vorontsova AV, Chelysheva EI, Gusarova GA, Kuznetsov SV, Goriacheva SR, Sokolova MA, Abakumov EM, Stakhina OV, Domracheva EV, Misiurin AV, Khoroshko ND. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase]. TERAPEVT ARKH 2009; 81:41-46. [PMID: 19708572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
AIM To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. MATERIAL AND METHODS A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008. RESULTS Lethal outcomes during dasatinib treatment were absent. To September 2008, 16 (89%) patients were alive, 2 (11%) patients died of the disease progression after dasatinib discontinuation. A complete clinicohematological response was observed in all the patients. Major cytogenetic, complete cytogenetic, major molecular, complete molecular responses were achieved in 12 (67%), 10 (55%), 7 (39%) and 5 (28%) patients, respectively. Hematological and non-hematological toxicity occurred in 9 (50%) patients. Now 12 (67%) patients continue dasatinib treatment, in 6 (33%) patients the drug was discontinued. CONCLUSION The results from trials in Russian Hematological Research Center are the same as in the international study. Dasatinib is effective and well tolerated therapeutic option for imatinib-resistant patients with a chronic phase of CML.
Collapse
|
32
|
Stromskaya TP, Rybalkina EY, Kruglov SS, Zabotina TN, Mechetner EB, Turkina AG, Stavrovskaya AA. Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib. Biochemistry (Mosc) 2008; 73:29-37. [PMID: 18294126 DOI: 10.1134/s0006297908010045] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Imatinib mesylate (imatinib) is a new generation preparation that is now successfully used for treatment of cancer, particularly for chemotherapy of chronic myeloid leukemia (CML). Imatinib inhibits the activity of chimeric kinase BCR-ABL, which is responsible for the development of CML. The goal of this study was to investigate the role of a multidrug resistance protein, P-glycoprotein (Pgp), in the evolution of CML treated with imatinib. We demonstrate here that although imatinib is a substrate for Pgp, cultured CML cells (strain K562/i-S9), overexpressing active Pgp, do not exhibit imatinib resistance. Studies of CML patients in the accelerated phase have shown variations in the number of Pgp-positive cells (Pgp+) among individual patients treated with imatinib. During treatment of patients with imatinib for 6-12 months, the number of Pgp-positive cells significantly increased in most patients. The high number of Pgp+ cells remained in patients at least for 4.5 years and correlated with active Rhodamine 123 (Rh123) efflux. Such correlation was not found in the group of imatinib-resistant patients examined 35-60 months after onset of imatinib therapy: cells from the imatinib-resistant patients exhibited efficient Rh123 efflux irrespectively of Pgp expression. We also compared the mode of Rh123 efflux by cells from CML patients who underwent imatinib treatment for 6-24 months and the responsiveness of patients to this therapy. There were significant differences in survival of patients depending on the absence or the presence of Rh123 efflux. In addition to Pgp, patients' cells expressed other transport proteins of the ABC family. Our data suggest that treatment with imatinib causes selection of leukemic stem cells characterized by expression of Pgp and other ABC transporters.
Collapse
Affiliation(s)
- T P Stromskaya
- Institute of Carcinogenesis, Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia.
| | | | | | | | | | | | | |
Collapse
|
33
|
Chelysheva EI, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction]. TERAPEVT ARKH 2007; 79:49-53. [PMID: 17564019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
AIM To quantitatively determine minimal residual disease (MRD) by real-time polymerase chain reaction (PCR) in patients with a chronic phase (CP) of chronic myeloid leukemia (CML). MATERIALS AND METHODS A molecular response was analyzed in 53 CML CP patients with incomplete and complete cptogenetic response (ICR and CCR) during imatinib therapy (median follow-up 36 months). BCR-ABL gene type p210 expression was quantitatively determined by real-time PCR under the TaqMan technology (an ICycler IQ device). The beta2 microglobulin (beta2M) gene was used as a reference gene. The results were expressed as the ratio: the number of BCR-ABL copies to that of beta2M x 10(5), as well as the difference of the common logarithm (lg) of the baseline expression level (BEL) and the result obtained: CEL lg-result lg. RESULTS The study revealed a correlation of the results of real-time PCR with those of cytogenetic analysis and showed it possible to study not only bone marrow, but also peripheral blood. Some negative real-time PCR results were checked using more sensitive PCR techniques. MRD was identified in most CML patients showing ICR and CCR during imatinib therapy. The reduction in BCR-ABL transcript levels by less than 2 lg (as compared to BEL) was associated with a cytogenetic recurrence and that by less than 3 lg was associated with a permanent high cytogenetic response. In patients with a cytogenetic recurrence, the median of BCR-ABL transcript levels was higher than that in patients with a permanent stable or unstable cytogenetic response. An elevation of BCR-ABL transcript levels over time antedated the development of a cytogenetic recurrence. CONCLUSION Quantitative monitoring by real-time PCR gives additional information on the dynamics of MRD in CML patients treated with glivec and permits improvement of study protocols for patients with CML at complete clinicohematological and cytogenetic remission.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/therapeutic use
- Benzamides
- Biomarkers, Tumor/blood
- Biomarkers, Tumor/genetics
- Bone Marrow/pathology
- Female
- Fusion Proteins, bcr-abl/blood
- Fusion Proteins, bcr-abl/genetics
- Gene Expression Regulation, Leukemic/drug effects
- Genes, abl/genetics
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Male
- Neoplasm, Residual
- Piperazines/administration & dosage
- Piperazines/therapeutic use
- Pyrimidines/administration & dosage
- Pyrimidines/therapeutic use
- RNA, Messenger/genetics
- RNA, Neoplasm/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Sensitivity and Specificity
- beta 2-Microglobulin/blood
- beta 2-Microglobulin/genetics
Collapse
|
34
|
Ermakova TA, Chelysheva EI, Turkina AG, Sokolova MA, Zakharova AV, Danil'cheva ES, Misiurin AV. [Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response]. TERAPEVT ARKH 2007; 79:13-16. [PMID: 17926464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
AIM To study feasibility of hemopoiesis clonality determination in assessment of remission completeness in patients with chronic myeloid leukemia (CML) using polymerase chain reaction (PCR HUMARA). MATERIAL AND METHODS We have examined 28 patients with newly diagnosed CML, 10 CML patients with a complete cytogenetic response (CCR) to therapy with imatinib mesilate and/or alpha-interferon, 24 healthy control females. Twelve patients with untreated CML were homozygous by HUMARA gene (human androgenic receptor gene) and were withdrawn from the study. Leukocytes of peripheral blood from all the patients were investigated with PCR HUMARA for mono- or polyclonal hemopoiesis. Clonality was defined as allele proportion (a/p) of polymorphic loci of HUMARA gene. Remission completeness was confirmed cytogenetically and by molecular methods. RESULTS The value a/p in 10 patients with CCR varies from 0.69 to 1.33 and is similar to those in the control group. CONCLUSION The PCR HUMARA technique adequately assesses reduction of Ph-positive clone in CML patients with CCR and points to polyclonal hemopoiesis.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Alleles
- Antineoplastic Agents/therapeutic use
- Benzamides
- DNA, Neoplasm/genetics
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Hematopoiesis/physiology
- Humans
- Imatinib Mesylate
- Immunologic Factors/therapeutic use
- Interferon-alpha/therapeutic use
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Middle Aged
- Piperazines/therapeutic use
- Polymerase Chain Reaction
- Polymorphism, Genetic
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Pyrimidines/therapeutic use
- Receptors, Androgen/blood
- Receptors, Androgen/genetics
- Recovery of Function/genetics
- Remission Induction/methods
- Treatment Outcome
Collapse
|
35
|
Zaritskiĭ AI, Lomaia EG, Vinogradova OI, Druzhkova GA, Kolosheĭnova TI, Loria SS, Pospelova TI, Krylova IV, Kruglov SS, Kuznetsov SV, Chelysheva EI, Abakumov EM, Sokolova MA, Nemchenko IS, Zakharova ES, Goriacheva SR, Kolosova LI, Vakhrusheva MV, Liamkina AS, Chernova OA, Machiulaĭtene ER, Ivanova VL, Udal'eva VI, Shneĭder TV, Ogorodnikova IS, Zhuravlev VS, Zakharova AV, Martynkevich IS, Domracheva EV, Afanas'ev BV, Abdulkadyrov KM, Kovaleva LG, Khoroshko ND, Turkina AG. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia]. TERAPEVT ARKH 2007; 79:17-22. [PMID: 17926465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
AIM To reveal prognostically significant factors affecting efficacy of glivek therapy in untreated (duration of the disease < or = 6 months) and pretreated (duration of the disease > 6 months) patients with chronic myeloid leukemia (CML) in a chronic phase. MATERIAL AND METHODS A total of 338 patients (64 untreated and 274 pretreated) with a chronic-phase CML on glivek therapy entered the trial. RESULTS Five-year survival on glivek was high (89, 98 and 88% in untreated and pretreated patients, respectively). Incidence of transformation in the acceleration phase and blast crisis was low both in untreated and pretreated patients (1.6 and 11%, respectively) and correlated with the rate of a complete cytogenetic response (CCR). Untreated patients had no factors affecting treatment efficacy negatively, CCR probability was 96%. Blastemia, thrombocytosis and splenomegaly reduced CCR probability significantly in pretreated patients. Slow reduction of the tumor mass, late achievement of a complete hematological response and a cytogenetic response decreased probability of CCR. CONCLUSION Glivek is a drug of choice for patients with chronic-phase CML. High probability of CCR both in untreated and pretreated patients lowers the risk of the disease transformation into the phase of acceleration/blast crisis and raises overall survival in both groups.
Collapse
|
36
|
Sokolova MA, Khoroshko ND, Tsvetaeva NV, Turkina AG, Levina AA, Mamukova II, Rokhnianskaia AA, Sudarikov AB, Romanova EA, Vasil'ev SA, Sukhanova GA, Orel EB, Rudakova VE, Tutaeva VV, Manakova TE, Semenova EA, Kulikov SM. [Hyperhomocysteinemia--one of the factors underlying thrombotic complications in patients with chronic myeloproliferative diseases]. TERAPEVT ARKH 2007; 79:57-62. [PMID: 18220034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
AIM To assess incidence of hyperhomocysteinemia (HHC) in patients with chronic myeloproliferative diseases (CMPD) and to analyse possible correlation between an elevated concentration of plasma homocystein (HC) and thrombotic complications. MATERIAL AND METHODS The trial enrolled 61 patients: 39 CMPD patients with thrombotic complications and free of them, 22 nonhematological patients with thrombosis. The control group consisted of 40 healthy donors. The examination protocol included determination with standard methods of HC plasma concentration, platelet and plasma components of hemostasis, mutation of factor V Leiden gene, prothrombin and methylenetetrahydrofolate reductase (MTHFR). RESULTS Mean HC concentration in the serum in CMPD patients was 19 +/- 1.7 mcmol/l which appeared higher than in healthy donors (12 +/- 1.3 mcmol/l). The highest HC was in patients with subleukemic myelosis (SLM)--23 +/- 2.3 mcmol). No difference in HC concentration in plasma was observed in CMPD carriers of homo- or heteroxygous mutation of C667T gene or CMPD patients without the mutation. In CMPD content of factor VIII was higher in HHC than in normal HC (222 +/- 26.5 and 116 +/- 20%, respectively, p = 0.002). For von Willebrand factor 202 +/- 15.6 and 120 +/- 14.6%, respectively (p < 0.003). HC reduction in response to vitamin therapy was the greater the higher its initial level was. CONCLUSION There is correlation between HHC and thrombosis in CMPD patients. HC concentration may depend on the proliferative stage of CMPD. As HC is a significant independent factor of thrombotic complications risk, it is necessary to detect and treat HHC.
Collapse
|
37
|
O'Brien SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23:7697-702. [PMID: 16186597 DOI: 10.1200/jco.2005.02.4364] [Citation(s) in RCA: 163] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the maximum-tolerated dose (MTD), efficacy, safety, and pharmacokinetics of oblimersen sodium in patients with advanced chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS Eligible patients had relapsed or refractory CLL after treatment with fludarabine. Oblimersen was administered at doses ranging from 3 to 7 mg/kg/d as a 5-day continuous intravenous infusion in cycle 1 and as a 7-day continuous intravenous infusion in subsequent cycles every 3 weeks in stable or responding patients. RESULTS Forty patients were enrolled and treated (14 patients in phase I and 26 patients in phase II). Dose-limiting reactions in phase I included hypotension and fever, and the MTD for phase II dosing was established at 3 mg/kg/d. Two (8%) of 26 assessable patients achieved a partial response. Other evidence of antitumor activity included > or = 50% reduction in splenomegaly (seven of 17 patients; 41%), complete disappearance of hepatomegaly (two of seven patients; 29%), > or = 50% reduction of lymphadenopathy (seven of 22 patients; 32%), and > or = 50% reduction in circulating lymphocyte counts (11 of 22 patients; 50%). Adverse events included transient hypotension, fever, fatigue, night sweats, diarrhea, nausea, vomiting, hypokalemia, and cough. Plasma concentrations of oblimersen (parent drug) and its major metabolites were variable. Renal clearance represented only a small portion of total parent drug clearance. CONCLUSION Dosing with oblimersen sodium in patients with CLL is limited by development of a cytokine release syndrome that is characterized by fever, hypotension, and back pain. Oblimersen sodium has modest single-agent activity in heavily pretreated patients with advanced CLL, and further evaluation of its activity in combination with cytotoxic drugs is warranted.
Collapse
MESH Headings
- Adult
- Aged
- Dose-Response Relationship, Drug
- Female
- Gene Expression Regulation, Leukemic/drug effects
- Humans
- Infusions, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Male
- Maximum Tolerated Dose
- Middle Aged
- Oligonucleotides, Antisense/pharmacokinetics
- Oligonucleotides, Antisense/therapeutic use
- Prognosis
- Proto-Oncogene Proteins c-bcl-2/genetics
- Proto-Oncogene Proteins c-bcl-2/metabolism
- RNA, Messenger/metabolism
- Remission Induction
- Survival Rate
- Thionucleotides/pharmacokinetics
- Thionucleotides/therapeutic use
Collapse
Affiliation(s)
- Susan M O'Brien
- M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030-7305, USA.
| | | | | | | | | | | |
Collapse
|
38
|
Turkina AG, Kruglov SS, Druzhkova GA, Domracheva EV, Zakharova AV, Vinogradova OI, Sysoeva EP, Diachenko LV, Chelysheva EI, Zakharova ES, Abakumov EM, Kolosheĭnova TI, Kolosova LI, Ivanova TV, Zhuravlev VS, Nemchenko IS, Zingerman BV, Kurova ES, Triputen' NZ, Loriia SS, Kovaleva LG, Khoroshko ND. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]. TERAPEVT ARKH 2005; 77:42-7. [PMID: 16116908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
AIM Clinical practice with the drug glivek (imatinibe mesilate, ST1571) blocking activity of oncoprotein p210 shows that a cytogenetic response can be reached in 50-60% of patients with chronic myeloid leukemia (CML), in a late chronic phase (CP) in resistance to or intolerance of interferon alpha (IF-alpha) and in 24-43% of patients in the acceleration phase (AP). This study aimed at assessment of the rate and stability of a cytogenetic response (CR) and long-term results of survival in CML patients on glivek. MATERIAL AND METHODS Glivek was given to 195 CML patients (median of the treatment duration was 42 months, 1-156 months, of the patients' age--46 years). 79 patients were in CP, 116--in AP. The doses were 400 mg/day and 116 mg/day, respectively. Karyotype was studied before the treatment and later after each 6 months. RESULTS A considerable CR was achieved in 57% patients in CP and 44%--in AP. Of them complete CR was obtained in 48 and 35%, respectively. Marked CR is a favourable prognostic factor. Survival of patients with marked CR in CP (97% 0 and AP (89%) was significantly higher than without CR (58 and 47%, respectively, p < 0.05). Marked CR persisted in 95% cases in both phases of CML. In complete CR, a repeated study of karyotype revealed residual number of Ph+ cells both in CP and AP in 86% patients. This demonstrates necessity to take glivek continuously in achievement of a complete CR by karyotypic test. Glivek inhibits the disease progression, lowers annual lethality. 42-month (median of glivek treatment duration) overall survival reached 91 and 59% in CP and AP, respectively. CONCLUSION CR is an integral index prognosticating CML course. Survival rose significantly in patients with marked CR both in CP and AP of CML. Marked CR is persistent in continuous glivek therapy. The rate of a CR depends much on the disease stage.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Benzamides
- Biopsy
- Bone Marrow/pathology
- Cytogenetic Analysis
- Female
- Follow-Up Studies
- Fusion Proteins, bcr-abl
- Humans
- Imatinib Mesylate
- Karyotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Leukocyte Count
- Male
- Middle Aged
- Piperazines/therapeutic use
- Protein Kinase Inhibitors/therapeutic use
- Protein-Tyrosine Kinases/antagonists & inhibitors
- Pyrimidines/therapeutic use
- Retrospective Studies
- Survival Rate/trends
- Time Factors
- Treatment Outcome
Collapse
|
39
|
Nemchenko IS, Khoroshko ND, Turkina AG, Sokolova MA, Kokhno AV, Semenova EA, Zakharova AV. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. TERAPEVT ARKH 2005; 77:90-2. [PMID: 16116920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
|
40
|
Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LI, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG. [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. TERAPEVT ARKH 2005; 77:11-6. [PMID: 16116902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
AIM To develop an original therapeutic strategy in Ph-positive acute lymphoblastic leukemia (ALL). MATERIAL AND METHODS In November 2001 Hematological Research Center (HRC) initiated the study of chimeric BCR-ABL gene. During the first stage of the study (November 2001-July 2004), 18 primary ALL patients were recruited in HRC, from July 2004 to January 2005--16 patients in HRC, N.N. Burdenko Central Military Hospital, regional Samara hospital. The diagnosis of Ph-positive ALL was established in detection of translocation t(9;22) by standard cytogenetic test or fluorescent hibridization in situ with double signal (D-FISH), or by polymerase chain reaction with reverse transcription (RT-PCR). In detection of aberration of BCR-ABL gene the patients received stem hemopoietic cells, from June 2004 imatinib was added to chemotherapy in the period of induction and consolidation. RESULTS Incidence rate of BCR-ABL-positive ALL by standard cytogenetic test and D-FISH makes up 20%, by RT-PCR--25%. Differences in chimeric transcripts detectability by different methods may be explained by different sensitivity of the methods. Complete hematological remissions were achieved in the majority of the patients (6 of 8) irrespective of imatinib administration. Achievement of molecular remission in BCR-ABL-positive ALL occurs also in standard chemotherapy but molecular remissions begin 2-4 months later than clinicohematological ones. CONCLUSION In using imatinib combination with chemotherapy, molecular remission can be achieved simultaneously with hematological one. Long-term results will be analysed later.
Collapse
|
41
|
Nemchenko IS, Khoroshko ND, Turkina AG, Vinogradova OI, Sokolova MA, Abakumov EM, Semenova EA, Zakharova AV, Domracheva EV. [Glivek in the therapy of some forms of Ph- and bcr/abl-negative myeloproliferative diseases and a myeloproliferative variant of idiopathic hypereosinophilic syndrome]. TERAPEVT ARKH 2004; 76:87-90. [PMID: 15379136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
|
42
|
Diachenko LV, Zakharova AV, Aseeva EA, Turkina AG, Khoroshko ND, Vodinskaia LA, Udovichenko AI, Domracheva EV. [Molecular-cytogenetic monitoring of different regimens of treatment in patients with chronic myeloid leukemia]. TERAPEVT ARKH 2004; 76:41-4. [PMID: 15379126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
AIM To conduct molecular-cytogenetic monitoring of bone marrow cells in different regimens of chronic myeloid leukemia (CML) treatment. MATERIAL AND METHODS A total of 651 samples of bone marrow from 319 CML patients were studied. 229 patients received polychemotherapy and 90 patients--interferon-alpha. Primary examination and monitoring of the treatment efficacy were performed using G-differential chromosome staining. Fluorescent in situ hybridization (FISH) was made in 75% cases. RESULTS Interferon therapy resulted in a significant increase in the number of complete and significant cytogenetic responses. With aggravation of the disease the above responses occurred less frequently while minor and no response are encountered more often. Treatment with interferon-alpha in combination with chemotherapy is much more effective than monotherapy with interferon. CONCLUSION G-differential chromosome staining karyotypes metaphases and detects clonal chromosome restructuring. Molecular-cytogenetic methods study chromosome restructuring at DNA level. FISH detects chimeric gene bcr/abl in cases when Ph-chromosome is not detectable by standard cytogenetic methods.
Collapse
|
43
|
Khoroshko ND, Turkina AG, Kumas SM, Zhuravlev VS, Kuznetsov SV, Sokolova MA, Semenova EA, Kaplanskaia IB, Frank GA, Korolev AV, Shcherbinina LA, Zakharova AV, Domracheva EV, Zingerman BA. [Prediction of interferon therapy efficacy in chronic myeloid leukemia according to data of histomorphological study]. TERAPEVT ARKH 2004; 76:44-50. [PMID: 15379127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
AIM To investigate factors determining prognosis and efficacy of induction therapy including interferon-alpha-2b (intron-A, Schering Plough) in patients at an early chronic stage of Ph-positive chronic myeloid leukemia (CML) as shown by histomorphological examination. MATERIAL AND METHODS The analysis covered 52 CML patients treated at an early chronic phase with intron-A in a standard daily dose 5 IU/m2 in combination with low-dose cytosinearabinoside (10 mg/m2, s.c. , daily for 10 days of each month). The treatment efficacy was assessed by the international criteria of complete and partial hematological remission and cytogenetic response. The cytogenetic study employed the direct method, even and G-differential staining, fluorescent hybridization in situ (FISH). The sections were stained with hematoxilin-eosine by Gomori, van Gieson. Histological samples were examined with histomorphometry. Immunohistochemical examination was made on paraffin sections using a panel of monoclonal antibodies CD3, CD4, CD8, CD20, NK, PCNA, Ki-67 (Dako, Denmark). RESULTS Repeated assessment of histomorphological parameters such as erythroid lineage, degree of myelofibrosis and reduction of leukemic population indicate the treatment efficacy. Estimation of the level of leukemic population proliferation in trephine biopsies from CML patients with monoclonal antibodies PCNA and Ki-67 before the treatment is prognostically significant as it further correlates with the cytogenetic response (r = 0.821, p = 0.000000). CONCLUSION It is valid to study histomorphological picture of CML to prognosticate and assess treatment efficacy with standard doses of interferon-alpha with high probability.
Collapse
|
44
|
Semenova EA, Turkina AG, Zakharova AV, Domracheva EV, Khoroshko ND, Frank GA. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha]. Arkh Patol 2003; 65:9-12. [PMID: 14518186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Trepanobiopsies of the bone marrow were studied in 46 patients in a chronic phase of chronic myeloid leukemia in different periods after the beginning of interferon-alpha therapy. Progression of myelofibrosis was observed in 2 cases only. Regression of myelofibrosis was observed in 14 cases of 29 (34.2%). A negative correlation between reticulin myelofibrosis and response to therapy was found. Disappearance of diffuse reticulin myelofibrosis in all cases was followed by a cytogenetic response.
Collapse
|
45
|
Turkina AG, Khoroshko ND, Druzhkova GA, Zingerman BV, Zakharova ES, Chelysheva EI, Vinogradova OI, Domracheva EV, Zakharova AV, Kovaleva LG. [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia]. TERAPEVT ARKH 2003; 75:62-7. [PMID: 14520855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
AIM To evaluate efficacy and tolerance of glivek in chronic myeloid leukemia (CML) in patients who failed interferon-alpha (If-a) preparations. MATERIAL AND METHODS 79 patients in a chronic phase of Ph + CML with hematological and cytogenetic resistance or intolerance of If-a. The response to glivec was assessed by achievement of a complete hematological remission and the cytogenetic effect (the degree of reduction of cell clone Ph+ in bone marrow). Tolerance and safety of the drug was studied by monthly standard clinicohematological tests. RESULTS Not only a hematological remission (92.4%), but also partial (46.8%) or complete (27.8%) elimination of BCR-ABL +/- cells were achieved after 12 months of the treatment. Glivec was well tolerated. Hematological toxicity primarily as neutropenia and thrombocytopenia were observed in 54.4 and 42% patients, respectively. Neutropenia of the third degree which made impossible to continue the treatment was observed in 29.1% patients; throbocytopenia of the third degree was registered in 16.5% patients. Among most frequent non-hematological side effects there were moderate edema, nausea, leg muscle convulsions, weight gain, arthralgias, skin eruption. All the complications were transient, were managed in all cases with only a short-time discontinuation of glivec therapy. CONCLUSION High activity of glivec at early stages of CML allows using this drug as a first-line therapy in patients with CML.
Collapse
|
46
|
Tsvetaeva NV, Vinogradova OI, Levina AA, Tsibul'skaia MM, Diagileva OA, Sokolova MA, Kuznetsov SV, Turkina AG, Khoroshko ND. [Clinical significance of erythrocyte ferritin in refractory anemia and chronic myeloid leukemia]. TERAPEVT ARKH 2002; 74:18-22. [PMID: 12181828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
AIM To find out if the RBC ferritin elevation can serve as an additional criterion of inefficient erythropoiesis during progression of chronic myeloid leukemia (CML) and in various types of refractory anemia. MATERIAL AND METHODS The study group consisted of 56 MDS patients and 73 patients at various stages of CML. 20 healthy donors and 105 patients with verified inefficient erythropoiesis (20--with B12 deficiency before and after the treatment, 85--with beta-thalassemia) were the controls. A ferritin level was measured by radioimmunoassay in RBC hemolysates. RESULTS The RBC ferritin level in all types of refractory anemia was elevated throughout the disease course, increasing with the development of transfusion dependency. The CML progression was also accompanied by RBC ferritin level elevation associated with abnormal erythroid cell accumulation and elevation of intracellular PAS-positive substance (p < 0.05). CONCLUSION RBC ferritin level elevation can be considered as an additional biochemical criterion of inefficient erythropoiesis that may be useful in differentiation of anemias, adequate therapy selection and follow-up of erythropoiesis.
Collapse
|
47
|
Stromskaia TP, Rybalkina EI, Turkina AG, Zabotina TN, Logacheva NP, Zakharova ES, Mechetner EB, Baryshnikov AI, Khoroshko ND, Stavrovskaia AA. [Functional activity and expression of P-glycoprotein in chronic myeloid leukemia]. TERAPEVT ARKH 2002; 73:20-5. [PMID: 11523404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
AIM To evaluate the prognostic significance of P-glycoprotein (Pgp) in chronic myeloid leukemia (CML). MATERIALS AND METHODS Functional activity (rhodamine 123 test) and expression of Pgp (binding of UIC2 monoclonal antibodies by cells) were evaluated by flow cytofluorometry. A total of 141 samples of peripheral blood from 121 patients with various stages of CML were examined. RESULTS The number of patients whose cells express functionally active Pgp increases during the blast crisis (BC) in comparison with the chronic phase (CP). Repeated testing of patients with BC and CP showed that Pgp-expressing cells can disappear from the peripheral blood of patients despite the treatment by Pgp preparations and substrates. However the number of cases with expression and functional activity of Pgp increases in the course of BC. Several patients in whom functionally active Pgp was not detected during diagnosis of BC had longer BC phase than patients with the active protein. CONCLUSION These data suggest that active Pgp contributes to CML BC (presumably to patient's response to therapy) but this contribution is not decisive.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology
- Adult
- Aged
- Antibodies, Monoclonal
- Blast Crisis/diagnosis
- Data Interpretation, Statistical
- Drug Resistance, Multiple
- Flow Cytometry
- Fluorescent Dyes
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
- Middle Aged
- Prognosis
- Rhodamine 123
Collapse
|
48
|
Kolodeĭ SV, Sokolova MA, Turkina AG, Khoroshko ND. [The estimation of thrombocytopoiesis using automated blood analyzers]. Klin Lab Diagn 2001:38-41. [PMID: 11521597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
|
49
|
Mokeeva RA, Tsvetaeva NV, Semenova EA, Turkina AG, Kuznetsova VP, Soboleva NN, Zavadenko MA, Khoroshko ND. [Cardiac pathology in idiopathic hypereosinophilic syndrome]. TERAPEVT ARKH 2001; 72:59-62. [PMID: 11201837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
50
|
Turkina AG, Logacheva NP, Stromskaya TP, Zabotina TN, Kuznetzov SV, Sachibzadaeva KK, Tagiev A, Juravlev VS, Khoroshko ND, Baryshnikov AY, Stavrovskaya AA. Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML). Adv Exp Med Biol 1999; 457:477-88. [PMID: 10500825 DOI: 10.1007/978-1-4615-4811-9_52] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
CML is the myeloproliferative disorder connected with the specific chromosome translocation (9;22) and occurrence of the fusion gene/protein BCR-ABL. BCR-ABL protein is believed to inhibit apoptosis and to cause drug resistance. We investigated the correlation of two different forms of BCR-ABL mRNA in 94 pts with their overall survival. It was found that b2a2 (but not b2a3) mRNA expression correlates with longer survival of patients treated with chemotherapy. We did not find an influence of different types of BCR/ABL mRNA on the survival of pts treated with interferon-alpha. FAS/APO-1 antigen was expressed by the cells of 34% of the pts in CML blast crisis (BC) and directly correlated with the the expression of CD34, CD13 and CD14 differentiation antigens. FAS/APO-1 non-expression correlated with higher rate of remissions in BC. We investigated P-glyco-protein (Pgp) expression and functional activity in 40 BC CML pts. 2-fold shorter survival was found in the pts with Pgp expression. Pgp expression strongly correlated with CD13 antigen. Consecutive studies of pts in BC CML show that Pgp expressing cells often do not multiply in the course of BC CML. We postulate that Pgp may be regarded as differentiation marker of the cells and the unfavorable prognostic factor in BC CML.
Collapse
MESH Headings
- ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics
- Apoptosis
- Chromosomes, Human, Pair 22
- Chromosomes, Human, Pair 9
- Drug Resistance, Multiple
- Female
- Fusion Proteins, bcr-abl/genetics
- Genes, MDR
- Humans
- Immunophenotyping
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality
- Male
- Prognosis
- Reverse Transcriptase Polymerase Chain Reaction
- Survival Rate
- Translocation, Genetic
- fas Receptor/analysis
Collapse
Affiliation(s)
- A G Turkina
- Haematological Research Centre of Russian Academy of Medical Sciences, Moscow, Russia
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|